Comparison of the Effects of Intermittent Fasting and Frequent Feeding Strategies on Weight Loss in Obese Women

This study was conducted to compare the effects of a 12-week 16:8 Time-Restricted Feeding (Intermittent Fasting) + home-based exercise protocol with and a calorie-restricted Standard Diet (SD) + home-based exercise protocol on body composition, lipid profile, glycemic control, and liver function enzyme levels in obese women.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obese or Overweight Healthy Volunteers Behavior Body Weight Fasting Feeding Behavior Intermittent Fasting Motor Activity Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

45 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Erciyes University

Kayseri, 38100, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Body Mass Index between 30 and 40
Female
Agreeing to adhere to a calorie-restricted diet
Agreeing to adhere to an exercise program

Exclusion criteria

Having cancer, diabetes, or thyroid disease
Having received assistance with weight loss in the last 3 months
Inability to adhere to calorie restriction
Failure to adhere to an exercise program

Treatment and study plan

16:8 Time-Restricted Feeding and Exercise

Other

Participants followed a 16:8 time-restricted feeding protocol (fasting for 16 hours and consuming all daily caloric intake within an 8-hour window) combined with a structured home-based exercise program for 12 weeks.

Standart Diet and Exercise

Other

Participants followed a standard energy-restricted diet distributed across regular daily meals combined with a structured home-based exercise program for 12 weeks

Primary outcomes

Changes in Glucose Metabolism, Lipid Profile, and Liver Enzymes

Time frame: Baseline and 12 weeks

Evaluation of changes in glucose metabolism (fasting glucose, fasting insulin, HOMA-IR), lipid profile (total cholesterol, HDL, LDL, triglycerides), and liver function enzymes (ALT, AST) from baseline to the end of 12 weeks.

Sponsors and collaborators

Lead sponsor

TC Erciyes University

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Sep 17, 2026
Registry last updated: Sep 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, not recruiting